Derm Cases · Dermatology / Paediatrics / Genodermatoses
OSCE — neonatal blistering: epidermolysis bullosa subtype, IFM, and RDEB SCC risk
An 8-minute OSCE on EB classification by cleavage plane, immunofluorescence mapping, multidisciplinary care, beremagene geperpavec concept, and high cumulative cSCC risk in severe RDEB.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE on EB classification by cleavage plane, immunofluorescence mapping, multidisciplinary care, beremagene geperpavec concept, and high cumulative cSCC risk in severe RDEB.
Brief (to candidate)
A neonate develops widespread blisters after minor handling. Parents ask whether this is “just fragile skin.” You have 8 minutes to classify EB, plan urgent diagnosis, outline supportive care, and state SCC risk in severe RDEB plus modern gene-therapy concepts.
Candidate instructions
- Classify EBS / JEB / DEB / Kindler by cleavage plane and key genes.
- Plan biopsy for immunofluorescence mapping (IFM) + genetics — not random punch alone.
- Outline wound care, infection, nutrition MDT principles.
- State cSCC cumulative risk in severe RDEB and biopsy triggers.
- Mention topical gene therapy (B-VEC / beremagene geperpavec) for dystrophic EB in approved settings.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Classification | EBS intraepidermal (often KRT5/14); JEB lamina lucida (laminin-332, COL17A1); DEB sublamina densa (COL7A1/type VII collagen); Kindler mixed (FERMT1)[1][2] |
| Urgent diagnosis | Specialist EB pathway; IF mapping on induced/fresh blister edge + genetic confirmation; avoid traumatic handling and adhesive trauma[1] |
| JEB airway red flag | Herlitz-type JEB: periorificial granulation, hoarseness/stridor → airway risk; intensive care liaison |
| Supportive care | Non-adherent dressings, gentle cleansing, pain control, high-calorie nutrition, iron/zinc, infection surveillance; no routine rough debridement of every blister without specialist method[3] |
| RDEB SCC | Severe RDEB: cumulative cutaneous SCC risk ~90% by mid-adulthood in classic registry data; biopsy chronic non-healing wounds/nodules urgently; SCC leading cause of early adult death in severe RDEB[4][1] |
| Advanced therapy | Beremagene geperpavec (B-VEC) topical HSV-1 vector COL7A1 gene therapy improves wound closure in dystrophic EB in pivotal trial settings; MDT access pathways vary by region[5] |
| Communication | Genetic counselling; realistic prognosis by subtype; avoid blaming parents for “rough handling” without education |
Model key actions
- Map blister plane with IFM + genetics before definitive subtype counselling.[1]
- Treat severe RDEB as lifelong wound + nutrition + SCC surveillance disease.[4]
- Know B-VEC as disease-modifying topical gene therapy for DEB wounds where available.[5]
Common errors
- Incising/debriding aggressively like ordinary bullous impetigo.[3]
- Missing laryngeal risk in JEB-Herlitz.
- Underestimating SCC risk in chronic RDEB wounds.
- Confusing inherited EB with epidermolysis bullosa acquisita (autoimmune, later onset).
References5ShowHide
- [1]Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primers, 2020.PMID 32973163
- [2]Hon KL, Chu S, Leung AKC Epidermolysis Bullosa: Pediatric Perspectives. Children, 2022.PMID 34036913
- [3]Danescu S, Negrutiu M, Has C Treatment of Epidermolysis Bullosa and Future Directions: A Review. Am J Clin Dermatol, 2024.PMID 39090514
- [4]Fine JD, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol, 2009.PMID 19026465
- [5]Guide SV, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med, 2022.PMID 36516090